泰德醫藥(3880.HK)今日在港掛牌上市漲近4%
多肽CRDMO新貴”泰德醫藥(3880.HK)今日首日在港掛牌上市,盤初一度漲近4%報31.8港元;該股IPO定價30.6港元,每手100股,公開發售獲301.15倍認購。據弗若斯特沙利文資料顯示,2023年,按銷售收入計,泰德醫藥是全球第三大專注於多肽的CRDMO,市場份額爲1.5%。公司也是全球專注於多肽的最全面的CRDMO之一,提供從早期發現、臨牀前研究及臨牀開發以至商業化生產的全週期服務。財務數據方面,公司2022年-2024年收益分別爲人民幣3.51億元、人民幣3.37億元及人民幣4.42億元;同期毛利分別爲人民幣2.01億元、人民幣1.80億元及人民幣2.49億元;年內利潤分別爲人民幣5398萬元、人民幣4890.5萬元及人民幣5917.3萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.